Severe osteogenesis imperfecta: new therapeutic options?

Publisher Website
Google Scholar
Abstract
References 1.↵ Marini JC .Osteogenesis imperfecta: managing brittle bones.N Engl J Med1998; 339:986–987. 2.↵ Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R .Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.N Engl J Med1998; 339:947–952. 3.↵ Horwitz EM, Prockop DW, Fitzpatrick LA, Koo WWK, Gordon PL, Neel M, et al .Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta.Nat Med1999; 5:309–313. 4.↵ Russell RGG, Rogers MJ .Bisphosphonates: from the laboratory to the clinic and back again.Bone1999; 25:97–106. 5.↵ Brumsen C, Handy NAT, Papapoulos SE .Long term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis.Medicine1997; 76:266–283. 6.↵ Bembi B, Parma A, Bottega M .Ceschel S, Zanatta M, Martini C, et al. Intravenous pamidronate treatment in osteogenesis imperfecta.J Pediatrics1997; 131:622–625. 7.↵ Pereira RF, O'Hara MD, Laptev AV, Halford KW, Pollard MD, Class R, et al .Marrow stromal cells as a source of progenitor cells for non haematopoietic tissues in transgenic mice with a phenotype of osteogenesis imperfecta.Proc Natl Acad Sci USA1998; 95:1142–1147. 8.↵ Marini JC .Osteogenesis imperfecta calls for caution.Nat Med1999; 5:466. 9.↵ Bishop NJ .Osteogenesis imperfecta calls for caution.Nat Med1999; 5:466–467. 10.↵ Gerson SL .Mesenchymal stem cells: no longer second class marrow citizens.Nat Med1999; 5:262–264. 11.↵ Whyte MP, Kurtzburg J, Gottesman GS, McAlister WH, Coburn SP, Ryan LM, et al .Marked clinical and radiographic improvement in infantile hypophosphatasia transiently after haploidentical bone marrow transplantation.Bone1998; 25 (suppl): S191.